Bicara Therapeutics Inc. (BCAX) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -771.9%, revenue growth -2.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $17.87M |
| Revenue (TTM) | $0.0B |
| Net Margin | -771.9% |
| Return on Equity | -39.5% |
| Operating Margin (TTM) | -1199.9% |
| Current Ratio | 11.59 |
| Revenue Growth (YoY) | -2.3% |
| EPS Growth (YoY) | 64.0% |
| FCF Growth (YoY) | 73.0% |
| Price / Book | 3.23 |
| Price / Sales | 89.86 |
| FCF Yield | -8.9% |
| Altman Z-Score | 29.17 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
BCAX overview · BCAX earnings · BCAX KPIs · BCAX documents · BCAX ownership · BCAX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.